- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06233071
Drospirenone (3 mg) + Ethinyl Estradiol (0.02 mg) Tablets Relative to Yaz®
A Bioequivalence Study of Drospirenone (3 mg) + Ethinyl Estradiol (0.02 mg) Tablets Relative to Yaz® in Healthy Thai Female Volunteers Under Fasting Condition
Study Overview
Status
Conditions
Detailed Description
Title A Bioequivalence study of a randomized, open-label, single dose, two-way crossover design with two-period, two-treatment and two-sequence of Drospirenone (3 mg) + Ethinyl Estradiol (0.02 mg) Tablets relative to Yaz® in healthy Thai female volunteers under fasting condition.
Objectives The primary objective is to compare the rate and extent of absorption of a generic formulation with that of a reference formulation when given as equal labeled dose. The secondary objective is to evaluate the safety after oral administration of both test and reference formulation in healthy Thai female volunteers.
Study Design Randomized, open-label, single dose, two-way crossover design with two-period, two-treatment and two-sequence under fasting condition and at least 28 days washout period between the doses.
Sample Size 32 Healthy Human Thai female subjects. Two extra subjects if available, may be checked-in on the day of check in of period-I to compensate for any dropout prior to dosing of period-I. These subjects will be dosed if there are dropouts prior to dosing in period-I. If there are no dropouts, these subjects will be checked-out without being dosed after completion of dosing in period-I.
Drug-Product Test-Product: Drospirenone (3 mg) + Ethinyl Estradiol (0.02 mg) Tablets Reference-product: Yaz® (Drospirenone (3 mg) + Ethinyl Estradiol (0.02 mg) Tablets) Manufactured by: Bayer Weimar GmbH und Co. KG, Germany
Administration After an overnight fasting at clinical facility of at least 10 hours, each volunteer will receive a single dose of two tablets of Drospirenone (3 mg) + Ethinyl Estradiol (0.02 mg) Tablets of either test or reference with 250 mL of drinking water. Each volunteer will be allowed to drink water as desire except 1 hour before and after drug administration. The formulation is given in a crossover fashion as per the randomization schedule. After the administration, the subject's oral cavity will be checked by using flashlight to confirm complete medication and fluid consumption by pharmacist.
Blood Schedule In each period, a total of 21 blood samples (approximately 10 mL each) will be collected pre-dose (0 hour) and at 0.333, 0.667, 1.000, 1.333, 1.667, 2.000, 2.333, 2.667, 3.000, 3.500, 4.000, 4.500, 6.000, 8.000, 12.000, 16.000, 24.000, 36.000, 48.000 and 72.000 hours after study drug administration, respectively. The sample collection at 36.000, 48.000 and 72.000 hours after dosing will be on ambulatory basis (i.e. on separate visit.).
Sample Collection Blood samples will be collected through an indwelling catheter placed in a vein using disposable syringe or through fresh venipuncture with disposable syringes and needles. Approximately 10 mL blood sample will be collected and transferred to 2 sample collection tubes containing K3EDTA as anticoagulant at each sampling time point. After collection of blood samples from all the subjects at each time point, samples will be centrifuged at 4000 rpm for 5 minutes at 4±2°C. After centrifugation, the plasma will be divided equally into another 3 cryovials for approximately 1.5 mL per each cryovial, Each cryovial will be set as Original (O), Duplicate (D) and Triplicate (T), respectively. Thereafter, Cryovials containing plasma sample will be stored at -70±10 °C.
Analytical Method Drospirenone and Ethinyl Estradiol plasma concentration will be assayed as per international Guidelines/In-house SOP by using a UPLC-MS/MS method.
Pharmacokinetic Parameters Drospirenone Primary pharmacokinetic parameter: Cmax, AUC0→ 72 and secondary pharmacokinetic parameter: Tmax, T1/2, Kel will be determined from the plasma concentration data of analytes.
Ethinyl Estradiol Primary pharmacokinetic parameter: Cmax, AUC0→t, AUC0→∞ and secondary pharmacokinetic parameter: Tmax, T1/2, Kel, AUC % Extrap will be determined from the plasma concentration data of analytes.
Statistical Analysis Drospirenone ANOVA, two one-sided tests for bioequivalence, for log-transformed pharmacokinetic parameters Cmax, AUC0→72 will be performed.
Ethinyl Estradiol ANOVA, two one-sided tests for bioequivalence, for log-transformed pharmacokinetic parameters Cmax, AUC0t, AUC0→∞ will be performed.
Acceptance Criteria for Bioequivalence Drospirenone To be considered as bioequivalent, the 90% CI of Cmax, AUC0→72 of Drospirenone of test and reference products should be in the interval of 80-125% for the log-transformed data Ethinyl Estradiol To be considered as bioequivalent, the 90% CI of Cmax, AUC0→t, AUC0→∞ of Ethinyl Estradiol of test and reference products should be in the interval of 80-125% for the log-transformed data.
Study Type
Enrollment (Estimated)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: Sasitorn Kittivoravitkul, Ph.D.
- Phone Number: 022549008
- Email: sasitorn_k@bio-innova.com
Study Contact Backup
- Name: Somkiat Tatritorn, M.D.
- Phone Number: 022549008
- Email: somkiat_t@bio-innova.com
Study Locations
-
-
-
Bangkok, Thailand, 10110
- Recruiting
- Bio-innova
-
Contact:
- Sasitorn Kittivoravitkul, Ph.D
- Phone Number: 022549008
- Email: sasitorn_k@bio-innova.com
-
Contact:
- Somkiat Tatritorn, Tatritorn
- Phone Number: 022549008
- Email: somkiat_t@bio-innova.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Willingness to provide written informed consent prior to participate in the study.
- Healthy Thai female subjects are between 18 to 55 years of age.
- The Body Mass Index (BMI) ranges from 18.5 to 30 kg/m2.
- Comprehensive of the nature and purpose of the study and compliance with the requirement of the entire protocol and allow investigators to draw 7 mL of blood for monitoring subjects' safety after the completion of the study.
- Negative urine pregnancy test and no breast-feeding.
- Absence of significant diseases or clinically significant abnormal laboratory values on the laboratory evaluations, medical history or surgery during the screening. Some of the laboratory values e.g. Complete blood count etc. that out of the normal range will be carefully considered by physician.
Exclusion Criteria:
- History or evidence of allergy or hypersensitivity to Drospirenone or Ethinyl Estradiol or any related drugs or any of the excipients of this product.
- Subject with B.P. is Systolic B.P <90, ≥140 mm/Hg, Diastolic B.P <60, ≥90 mm/Hg, pulse rate >100 beats per minute.
- Serum bilirubin greater than 1.5 times the upper limit of reference range (ULRR).*
- Serum creatinine greater than 1.5 times the upper limit of reference range (ULRR).*
- Alanine amino transferase (ALT) or aspartate amino transferase (AST) greater than 2 times the upper limit of reference range (ULRR).*
- Positive of hepatitis B or C virus.
- Have more than one abnormal EKG, which is considered as clinically significant. *
- History or evidence of heart (heart attack, angina pectoris), renal, hepatic disease, adrenal insufficiency, pulmonary obstructive disease, bronchial asthma, hypertension, vascular disease (deep vein thrombosis, pulmonary embolism, venous thromboembolism, stroke, transient ischemic attack), migraine with aura, metabolic disorder, or glaucoma
- History or Family history of VTE in a first degree relative under the age of 45.
- History of abnormal vaginal bleeding or coagulopathy.
- History or Family history in a first degree of breast cancer.
- History or evidence of gastrointestinal disorder likely to influence drug absorption or previous GI surgery other than appendectomy.
- Any major illness in the past 3 months or any significant ongoing chronic medical illness.
- History of psychiatric disorder or depression.
- History of regular alcohol consumption exceeding 7 drinks/week for females (1 drink = 5 ounces (150 mL) of wine or 12 ounces (360 mL) of beer or 1.5 ounces (45 mL) of hard liquor) and cannot stop at least 2 days before the study drug administration and until the completion of each period of the study.
- History of usually smoking (more than 10 cigarettes per day within past 1 year), if moderate smokers (less than 10 cigarettes per day) cannot stop at least 7 days before the study drug administration and until the completion of each period of the study.
- High caffeine consumption (more than 5 cups of coffee or tea per day) and cannot stop at least 2 days before the study drug administration and until the completion of each period of the study.
- History of pomelo or grapefruit or grapefruit products consumption and cannot stop at least 7 days before the study drug administration and until the completion of each period of the study.
- History of St. John's Wort products consumption and cannot stop at least 28 days before the study drug administration and until the completion of the study.
- Positive drug abused test in urine (Benzodiazepines, Marijuana (THC), Methamphetamine, Cocaine and Opioids).
- Receipt of any prescription drug therapy within 14 days or 5 half-lives (whichever longer) preceding the first dose of study medication or over-the-counter (OTC) drugs or herbal medicines/food supplement within 7 days or hormonal methods of contraception within 28 days (Depo-Provera must be discontinued at least 6 months) prior to receiving the first dose of study medication.
- History of difficulty in accessibility of veins in left and right arm.
- Blood donation (one unit or 450 mL) within the past 3 months before the study.
- Participation in any clinical study within the past 3 months before the study.
- Subjects who are unwilling or unable to comply with the lifestyle guidelines described in this protocol.
(* Depend on decision of principal investigator and/or clinical investigator)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Sequence 1-Drospirenone+ Ethinyl Estradiol test product and then reference product
Participants will receive treatment 1 in period 1 and treatment 2 in period 2.
Where treatment 1= Drospirenone (3 mg) + Ethinyl Estradiol (0.02 mg) test product, treatment 2= Drospirenone (3 mg) + Ethinyl Estradiol (0.02 mg) reference product.
|
Drospirenone (3 mg) + Ethinyl Estradiol (0.02 mg) Tablets Manufactured by: POND'S CHEMICAL THAILAND R.O.P
|
Experimental: Sequence 2-Drospirenone+ Ethinyl Estradiol reference product and then test product
Participants will receive treatment 2 in period 1 and treatment 1 in period 2.
Where treatment 1= Drospirenone (3 mg) + Ethinyl Estradiol (0.02 mg) test product, treatment 2= Drospirenone (3 mg) + Ethinyl Estradiol (0.02 mg) reference product.
|
Drospirenone (3 mg) + Ethinyl Estradiol (0.02 mg) Tablets Manufactured by: Bayer Weimar GmbH und Co. KG, Germany
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Area under the plasma concentration-time curve from time zero to the last measurable concentration (AUC 0-t)
Time Frame: Blood samples will be collected for PK analyses in each period pre-dose (0 hour) and at 0.333, 0.667, 1.000, 1.333, 1.667, 2.000, 2.333, 2.667, 3.000, 3.500, 4.000, 4.500, 6.000, 8.000, 12.000, 16.000, 24.000, 36.000, 48.000 and 72.000 hours post-dose
|
pre-dose (0 hour) and at 0.333, 0.667, 1.000, 1.333, 1.667, 2.000, 2.333, 2.667, 3.000, 3.500, 4.000, 4.500, 6.000, 8.000, 12.000, 16.000, 24.000, 36.000,
48.000 and 72.000 hours post-dose
|
Blood samples will be collected for PK analyses in each period pre-dose (0 hour) and at 0.333, 0.667, 1.000, 1.333, 1.667, 2.000, 2.333, 2.667, 3.000, 3.500, 4.000, 4.500, 6.000, 8.000, 12.000, 16.000, 24.000, 36.000, 48.000 and 72.000 hours post-dose
|
Maximal measured plasma concentration (Cmax) of dutasteride test product and reference product
Time Frame: Blood samples will be collected for PK analyses in each period pre-dose (0 hour) and at 0.333, 0.667, 1.000, 1.333, 1.667, 2.000, 2.333, 2.667, 3.000, 3.500, 4.000, 4.500, 6.000, 8.000, 12.000, 16.000, 24.000, 36.000, 48.000 and 72.000 hours post-dose
|
pre-dose (0 hour) and at 0.333, 0.667, 1.000, 1.333, 1.667, 2.000, 2.333, 2.667, 3.000, 3.500, 4.000, 4.500, 6.000, 8.000, 12.000, 16.000, 24.000, 36.000,
48.000 and 72.000 hours post-dose
|
Blood samples will be collected for PK analyses in each period pre-dose (0 hour) and at 0.333, 0.667, 1.000, 1.333, 1.667, 2.000, 2.333, 2.667, 3.000, 3.500, 4.000, 4.500, 6.000, 8.000, 12.000, 16.000, 24.000, 36.000, 48.000 and 72.000 hours post-dose
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of subjects with adverse events
Time Frame: Approximately the day 28 after the last visit
|
An adverse event (AE) is any untoward medical occurrence in a clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.
|
Approximately the day 28 after the last visit
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Physiological Effects of Drugs
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Estrogens
- Natriuretic Agents
- Diuretics
- Hormone Antagonists
- Contraceptive Agents, Hormonal
- Contraceptive Agents
- Reproductive Control Agents
- Contraceptives, Oral
- Contraceptive Agents, Female
- Contraceptives, Oral, Hormonal
- Mineralocorticoid Receptor Antagonists
- Diuretics, Potassium Sparing
- Estradiol
- Ethinyl Estradiol
- Estradiol 17 beta-cypionate
- Estradiol 3-benzoate
- Polyestradiol phosphate
- Drospirenone
Other Study ID Numbers
- DRE-026-22
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy Subjects
-
BiogenCompletedHealthy Adult Subjects | Healthy Elderly SubjectsUnited States
-
PfizerCompletedHealthy Adult Subjects and Healthy Elderly SubjectsBelgium
-
Lund UniversityCompletedHealthy Subjects | Diet, HealthySweden
-
PfizerRecruitingHealthy Subjects | Healthy ParticipantsUnited States
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedHealthy | Healthy Subjects | ImmunosuppressionUnited States
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
NeuShen TherapeuticsNot yet recruiting
-
GEN İlaç ve Sağlık Ürünleri A.Ş.Sulfateq B.V.Recruiting
-
Bio-innova Co., LtdNot yet recruiting
-
Bio-innova Co., LtdNot yet recruiting
Clinical Trials on Drospirenone+ Ethinyl Estradiol Tablets-Test product
-
Bio-innova Co., LtdNot yet recruiting
-
NewAmsterdam PharmaNovumRecruitingHealthy VolunteersUnited States
-
Laboratorios Andromaco S.A.Completed
-
Teva Pharmaceuticals USACompletedHealthyUnited States
-
Teva Pharmaceuticals USACompletedHealthyUnited States
-
NewGiza UniversityAin Shams UniversityNot yet recruiting
-
Ain Shams Maternity HospitalUnknown
-
AGUNCO Obstetrics and Gynecology CentreCompleted
-
Bristol-Myers SquibbCompleted